Trials / Recruiting
RecruitingNCT06679036
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
An Open, Multicenter Phase Ib/II Clinical Study on the Safety, Tolerance, Pharmacokinetics, and Initial Efficacy of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-2189 | HRS-2189 |
| DRUG | Fluvustat | Fluvustat |
| DRUG | HRS-8080 | HRS-8080 |
| DRUG | HRS-6209 | HRS-6209 |
| DRUG | HRS-1358 | HRS-1358 |
Timeline
- Start date
- 2025-01-21
- Primary completion
- 2026-10-30
- Completion
- 2026-12-31
- First posted
- 2024-11-07
- Last updated
- 2026-03-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06679036. Inclusion in this directory is not an endorsement.